Partnership will expand use of next-generation sequencing (NGS) to
help diagnose patients quickly and more accurately

Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) and Trivitron Healthcare, one
of India’s largest medical technology companies, have entered into a strategic partnership to develop and expand the use
of next-generation sequencing (NGS)-based in-vitro diagnostic tests (IVD) in India.
Over the next four years, Illumina and Trivitron intends to develop and distribute a suite of standardized, commercial IVD
assays to deliver an eective and non-invasive way of diagnosing cancers, determining infectious pathogens, and
identifying prenatal diseases. The assays will be cost-eective, easy to use, and have high throughput capabilities.
“Illumina believes in democratizing access to sequencing. There is a vital need to make genomic technology and precision
medicine available to all.” said Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia
Pacific and Japan at Illumina.
Ms Weightman added “Our collaboration with Trivitron will increase access for patients in India to genomics and expand
on Illumina’s solid history and broad portfolio of partnerships with industry leaders, with the united goal of advancing
diagnostics and precision medicine.”
“We are pleased to announce our partnership with Illumina as we will be able to develop creative, adaptable, and scalable
solutions to address the demands of Indian patients as a result of our collaboration.” said Dr. GSK Velu, Chairman &
Managing Director, Trivitron Healthcare.
“With this partnership, Trivitron will build improved NGS-based diagnostic tests across a variety of disease categories on
Illumina’s sequencing technology as part of this collaboration. The improved and locally-designed diagnostic tests will be
manufactured and marketed by Trivitron following regulatory approvals.” he said.
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches
have demonstrated considerable increases in disease detection rates over other approaches. Similarly, tailored NGS
panels have allowed for the rapid, non-invasive, and cost-eective diagnosis and prognosis of a variety of malignancies,
as well as the detection of infectious pathogens and the identification of a variety of prenatal disorders.
In addition to this partnership, in August 2020, Illumina collaborated with the Institute of Genomics & Integrative Biology
in New Delhi to evaluate COVIDSeq and increase availability of frontline testing.